AIM ImmunoTech Inc (NYSE:AIM) has announced that safety data on its drug Ampligen was recently presented at the Eighth European Scientific Working Group on Influenza (ESWI) virtual conference in Salzburg, Austria.
The conference, which ran from December 4-7, 2021, also included research on coronavirus (COVID-19) and respiratory syncytial virus.
The immuno-pharma company said the Centre for Human Drug Research (CHDR) presented previously announced data from a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as a potential intranasal therapy.
READ: AIM ImmunoTech submits IND and Fast Track applications for Phase 2 trial of Ampligen pancreatic cancer therapy
A total of 40 healthy subjects received either Ampligen or a placebo in the trial, with the Ampligen given at four escalating dosages across four cohorts, to a maximum level of 1,250 micrograms. The study reported no severe adverse events at any dosage level, it added.
AIM said it expects to receive the full study report from the CHDR in January 2022.
AIM ImmunoTech is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.
Contact the author at stephen.gunnion@proactiveinvestors.com